InsiderSource

Alta Partners Management VIII, LLC

10% Owner, Director · SEC CIK 1399894
Insider at ALLK Allakos Inc. STRO SUTRO BIOPHARMA INC NEOT Neothetics, Inc. ZSPH ZS Pharma, Inc. LIFE aTYR PHARMA INC TRVN TREVENA INC AGTC APPLIED GENETIC TECHNOLOGIES CORP ESPR Esperion Therapeutics, Inc. IMDZ Immune Design Corp. ANSV ANESIVA, INC. ATSI ATS MEDICAL INC
Advertisement

Buy track record

How this insider's open-market purchases have performed
0%
of buys now in profit
0 up · 4 down
Avg return since buy−90.3%
Median return−90.3%
Best trade−80.5%
Worst trade−100.0%
Buys scored4 (+5 n/a)
Average return by holding period — separates good entry timing from riding one long winner
After 1 month +0.0% 0% won · 4 trades
After 3 months +0.0% 0% won · 4 trades
After 6 months +0.0% 0% won · 4 trades
After 12 months +0.0% 0% won · 4 trades
DateCompany90d trendBuy priceValueΔOwn1M3M6M12MTo date
Dec 10, 2014 TRVN $4 $2M +13% +0.0% +0.0% +0.0% +0.0% −100.0%
Oct 21, 2014 ESPR $20 $10M +24% +0.0% +0.0% +0.0% +0.0% −80.5%
Feb 5, 2014 TRVN $7 $3.31M +14% +0.0% +0.0% +0.0% +0.0% −100.0%
Jul 1, 2013 ESPR $14 $3.3M +13% +0.0% +0.0% +0.0% +0.0% −80.5%
How this is calculated. We score only open-market purchases (SEC code P) — the buys that carry real signal. Each trade's return is measured from the adjusted closing price on the purchase date to the latest close, accounting for stock splits and dividends. The 1M/3M/6M/12M columns show the same trade's return after each fixed holding period; a dash means that horizon hasn't elapsed yet or isn't priceable. Sales are excluded because insiders sell for many routine reasons. With only 4 scored trades, treat this as a small sample, not a verdict.
Advertisement
Open-market buys
$33.15M
9 trades
Open-market sells
$37.83M
19 trades
Net flow
−$4.68M
Net selling
Total filings
45
transactions shown

Full transaction history

All Form 4 activity across every company, newest first
View on SEC EDGAR ↗
Advertisement
ALLK
Allakos Inc.
Buy Alta Partners VIII, L.P. · 10% Owner · Open-market purchase · filed Jul 23, 2018 ΔOwn +2.2%

Alta Partners Viii, L.p., ALLK's 10% owner, spent $4.5M of their own money on 250,000 shares at $18, growing their stake 2%.

+$4.5M
250,000 sh @ $18
NEOT
Neothetics, Inc.
Sell Alta Partners VIII, L.P. · Insider · Open-market sale · filed Dec 30, 2015 ΔOwn −16%

Alta Partners Viii, L.p. sold $360K of NEOT, trimming their stake 16%.

−$360K
250,000 sh @ $1
NEOT
Neothetics, Inc.
Sell Alta Partners VIII, L.P. · Insider · Open-market sale · filed Dec 30, 2015 ΔOwn −24%

Alta Partners Viii, L.p. sold $755.3K of NEOT, trimming their stake 24%.

−$755.3K
493,654 sh @ $2
NEOT
Neothetics, Inc.
Sell Alta Partners VIII, L.P. · Insider · Open-market sale · filed Dec 30, 2015 ΔOwn −2.5%

Alta Partners Viii, L.p. sold $86.4K of NEOT, trimming their stake 3%.

−$86.4K
54,333 sh @ $2
NEOT
Neothetics, Inc.
Sell Alta Partners VIII, L.P. · 10% Owner · Open-market sale · filed Dec 17, 2015 ΔOwn −20%

Alta Partners Viii, L.p. sold $762.1K of NEOT, trimming their stake 20%.

−$762.1K
529,261 sh @ $1
ZSPH
ZS Pharma, Inc.
Sell Alta Partners VIII, L.P. · 10% Owner · Open-market sale · filed Jun 9, 2015 ΔOwn −5.8%

Alta Partners Viii, L.p. sold $9.51M of ZSPH, trimming their stake 6%.

−$9.51M
164,227 sh @ $58
ZSPH
ZS Pharma, Inc.
Sell Alta Partners VIII, L.P. · 10% Owner · Open-market sale · filed Jun 5, 2015 ΔOwn −1.4%

Alta Partners Viii, L.p. sold $2.26M of ZSPH, trimming their stake 1%.

−$2.26M
39,495 sh @ $57
ZSPH
ZS Pharma, Inc.
Sell Alta Partners VIII, L.P. · 10% Owner · Open-market sale · filed Jun 5, 2015 ΔOwn −1.7%

Alta Partners Viii, L.p. sold $2.82M of ZSPH, trimming their stake 2%.

−$2.82M
48,913 sh @ $58
ZSPH
ZS Pharma, Inc.
Sell Alta Partners VIII, L.P. · 10% Owner · Open-market sale · filed Jun 5, 2015 ΔOwn −0.8%

Alta Partners Viii, L.p. sold $1.31M of ZSPH, trimming their stake 1%.

−$1.31M
23,189 sh @ $57
ZSPH
ZS Pharma, Inc.
Sell Alta Partners VIII, L.P. · 10% Owner · Open-market sale · filed Jun 2, 2015 ΔOwn −2.8%

Alta Partners Viii, L.p. sold $4.79M of ZSPH, trimming their stake 3%.

−$4.79M
84,342 sh @ $57
ZSPH
ZS Pharma, Inc.
Sell Alta Partners VIII, L.P. · 10% Owner · Open-market sale · filed Jun 2, 2015 ΔOwn −2.3%

Alta Partners Viii, L.p. sold $4.21M of ZSPH, trimming their stake 2%.

−$4.21M
72,520 sh @ $58
ZSPH
ZS Pharma, Inc.
Sell Alta Partners VIII, L.P. · 10% Owner · Open-market sale · filed Jun 2, 2015 ΔOwn −3.9%

Alta Partners Viii, L.p. sold $7.32M of ZSPH, trimming their stake 4%.

−$7.32M
124,865 sh @ $59
TRVN
TREVENA INC
Buy Alta Partners VIII, L.P. · 10% Owner · Open-market purchase · filed Dec 10, 2014 ΔOwn +13%

Alta Partners Viii, L.p., TRVN's 10% owner, spent $2M of their own money on 500,000 shares at $4, growing their stake 13%.

+$2M
500,000 sh @ $4
NEOT
Neothetics, Inc.
Option exercise JANNEY DANIEL · Director, 10% Owner · Option exercise · filed Nov 25, 2014 ΔOwn +3.7%
+$1.06M
93,676 sh @ $11
NEOT
Neothetics, Inc.
Sell JANNEY DANIEL · Director, 10% Owner · Open-market sale · filed Nov 25, 2014 ΔOwn −2.2%

Janney Daniel sold $800K of NEOT, trimming their stake 2%.

−$800K
57,143 sh @ $14
NEOT
Neothetics, Inc.
Option exercise JANNEY DANIEL · Director, 10% Owner · Option exercise · filed Nov 25, 2014 ΔOwn +4.6%
+$990K
115,925 sh @ $9
NEOT
Neothetics, Inc.
Sell JANNEY DANIEL · Director, 10% Owner · Open-market sale · filed Nov 25, 2014 ΔOwn −2.7%

Janney Daniel sold $990K of NEOT, trimming their stake 3%.

−$990K
70,714 sh @ $14
NEOT
Neothetics, Inc.
Option exercise JANNEY DANIEL · Director, 10% Owner · Option exercise · filed Nov 25, 2014 ΔOwn +1.4%
+$300K
35,128 sh @ $9
NEOT
Neothetics, Inc.
Sell JANNEY DANIEL · Director, 10% Owner · Open-market sale · filed Nov 25, 2014 ΔOwn −0.8%

Janney Daniel sold $300K of NEOT, trimming their stake 1%.

−$300K
21,429 sh @ $14
NEOT
Neothetics, Inc.
Buy JANNEY DANIEL · Director, 10% Owner · Open-market purchase · filed Nov 25, 2014 ΔOwn +2.7%

Janney Daniel, NEOT's 10% owner, spent $980K of their own money on 70,000 shares at $14, growing their stake 3%.

+$980K
70,000 sh @ $14

Frequently asked questions

How is Alta Partners Management VIII, LLC's win rate calculated?

We take every open-market purchase (SEC code P) we can match to a stock price, then compare the split- and dividend-adjusted price on the purchase date to the most recent close. The win rate is the share of those buys currently trading above the purchase price. Sales and share grants are not scored.

Why are some buys not included in the score?

A purchase is excluded if we can't price it — for example if the ticker is missing from the filing, the company has been delisted, or the security isn't a common stock we can match to market data. Excluded counts are shown next to the scored total.

What do the 1M / 3M / 6M / 12M columns mean?

They show each purchase's return after a fixed holding period — one, three, six, and twelve months from the buy date — using split- and dividend-adjusted prices. This separates good entry timing from simply holding a long-running winner. A dash means that horizon hasn't elapsed yet for that trade, or the stock couldn't be priced at that date.

Does a high win rate mean I should copy this insider?

No. Past performance does not predict future results, sample sizes are often small, and an insider's edge in their own company doesn't transfer to yours. This is context, not a recommendation. InsiderSource is not investment advice.

Where does this data come from?

Trades come from Alta Partners Management VIII, LLC's SEC Form 4 filings on EDGAR. Prices come from public market data and are split/dividend-adjusted. Always verify against the original filings before acting.